Exploring new MRI techniques for head and neck cancers
Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers
Memorial Sloan Kettering Cancer Center · NCT03483337
This study is testing new MRI techniques to see if they can give better details about head and neck tumors in patients getting treatment for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT03483337 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate new MRI methods to gather more detailed information about tumors in patients with head and neck cancers, including thyroid cancer. By utilizing diffusion MRI, the study will measure the movement of water within tumors, potentially enhancing diagnostic capabilities. Participants will undergo MRI examinations to assess the effectiveness of these new biomarkers in identifying metastatic or recurrent disease. The study focuses on patients who are already planning to receive treatment at Memorial Sloan Kettering Cancer Center.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspicious metastatic lesions or confirmed recurrent head and neck cancers, as well as thyroid cancers.
Not a fit: Patients who are claustrophobic, require anesthesia for the MRI, or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment planning for patients with head and neck cancers.
How similar studies have performed: Other studies have shown promise in using advanced MRI techniques for cancer diagnostics, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region. * Group 2 patients: * Biopsy proven recurrent or metastatic or definitive head and neck cancer or (differentiated and undifferentiated) thyroid cancers in the head and neck region only. * Patients planning to undergo reatment at MSK Exclusion Criteria: * Patient would require anesthesia for the study * Patients who are claustrophobic * Patients selecting treatment outside of MSK * Known reaction to Gd based contrast agent * Patients who have presence of a known contradiction to MRI * Pacemaker * Aneurysm clips * Patients with implants that are contradicted for MR imaging will be excluded * Pregnant * Age and mental status wherein he /she is unable to cooperate for MRI study
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Amita Dave, PhD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Amita Dave, PhD
- Email: davea@mskcc.org
- Phone: 212-639-3184
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Head and Neck Cancer, Thyroid Cancer, -MRI, oncological biomarkers, metastatic, recurrent, 18-063